Brain Metastasis from Breast Cancer - Pipeline Insight, 2024

This “Brain Metastasis from Breast Cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Brain Metastasis from Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Brain Metastasis from Breast Cancer Understanding

Brain Metastasis from Breast Cancer: Overview

Central nervous system or brain metastases traditionally occur in 10-16% of metastatic breast cancer patients and are associated with a dismal prognosis. The development of brain metastases has been associated with young age, and tumors that are estrogen receptor negative, Her-2+ or of the basal phenotype. Diagnosis can be done through MRI (magnetic resonance imaging) study of the brain.In rare cases, biopsies are performed to confirm the diagnosis. Neuroimaging, staging, and diagnostic neuropathology can also be done. Treatment typically includes whole brain irradiation, or either stereotactic radiosurgery or surgery with whole brain radiation, resulting in an approximately 20% one year survival. The blood-brain barrier is a formidable obstacle to the delivery of chemotherapeutics to the brain. Under chemotherapy, etirinotecan pegol has promising results and in Abemaciclib as a targeted therapies can also be seen. Lapatinib, a small molecule with potential ability to cross the BBB, has been extensively tested in the treatment of HER2-positive brain metastases.

Brain Metastasis from Breast Cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Brain Metastasis from Breast Cancer pipeline landscape is provided which includes the disease overview and Brain Metastasis from Breast Cancer treatment guidelines. The assessment part of the report embraces, in depth Brain Metastasis from Breast Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain Metastasis from Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Brain Metastasis from Breast Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Brain Metastasis from Breast Cancer.

Brain Metastasis from Breast Cancer Emerging Drugs Chapters

This segment of the Brain Metastasis from Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Brain Metastasis from Breast Cancer Emerging Drugs

ANG1005: Angiochem ANG-1005 is a peptide-drug conjugate containing paclitaxel covalently linked to a peptide (Angiopep-2). The drug gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the Blood brain barrier. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain. A Phase III clinical trial is evaluating ANG-1005 to treat brain metastasis associated with breastcancer.

Pembrolizumab: Merck Sharp & Dohme Pembrolizumab is a medication used in the management and treatment of various oncologic conditions. It is in the cancer immunotherapy class of drugs. KEYTRUDA binds to the PD?-?1 receptor, blocking both immune-suppressing ligands, PD-L1 and PD-L2, from interacting with PD?-?1 to help restore T-cell response and immune response. The drug is currently being evaluated in Phase I/II stage of development for the treatment of patients with Brain Metastases In Breast CancerPatients.

Brain Metastasis from Breast Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Brain Metastasis from Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Brain Metastasis from Breast Cancer

There are approx. 10+ key companies which are developing the therapies for Brain Metastasis from Breast Cancer. The companies which have their Brain Metastasis from Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Angiochem.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Brain Metastasis from Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Brain Metastasis from Breast Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Brain Metastasis from Breast Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Brain Metastasis from Breast Cancer drugs.

Brain Metastasis from Breast Cancer Report Insights

• Brain Metastasis from Breast Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Brain Metastasis from Breast Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Brain Metastasis from Breast Cancer drugs?
• How many Brain Metastasis from Breast Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Brain Metastasis from Breast Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Brain Metastasis from Breast Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Brain Metastasis from Breast Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 1-3 business days.